Cargando…
Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study
Several clinically approved recombinant erythropoietin (rEPO) preparations, such as epoetin-β, epoetin-δ and the epoetin-α derivative, darbepoetin-α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861354/ https://www.ncbi.nlm.nih.gov/pubmed/24348759 http://dx.doi.org/10.3892/etm.2013.1384 |
_version_ | 1782295617664450560 |
---|---|
author | OHTA, SHOICHIRO YASUNO, NOBUHIRO INOMOTO, YUKI MATSUDA, KAORI NAKAGAWA, YOSHIHIKO SASAGAWA, ISOJI TANAKA, MASAHIKO |
author_facet | OHTA, SHOICHIRO YASUNO, NOBUHIRO INOMOTO, YUKI MATSUDA, KAORI NAKAGAWA, YOSHIHIKO SASAGAWA, ISOJI TANAKA, MASAHIKO |
author_sort | OHTA, SHOICHIRO |
collection | PubMed |
description | Several clinically approved recombinant erythropoietin (rEPO) preparations, such as epoetin-β, epoetin-δ and the epoetin-α derivative, darbepoetin-α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market. In 2010, epoetin-κ, which is biosimilar to epoetin-α, was clinically approved. Epoetin-κ is a biopharmaceutical product that is based on serum-free media following master cell bank preparation. The present study analyzes the results obtained during a six-month observation period, in which the administration of epoetin-β was switched to that of epoetin-κ. In a cohort of patients receiving chronic dialysis, who were clinically in a state of relative calm and were in control of their renal anemia, it was possible to sustain good control of the anemia by reducing the frequency of the epoetin-β administration from the conventional and empirically determined three times a week to twice a week, and further to once a week. Furthermore, the good control was maintained upon changing from the administration of epoetin-β to that of epoetin-κ. Moreover, three months subsequent to this switch, the degree of instability observed among the patients had decreased. Despite the fact that the situation following the changeover requires further investigation, it may be concluded that the results obtained in this study are indicative of the clinical equivalence and efficacy of epoetin-κ. |
format | Online Article Text |
id | pubmed-3861354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-38613542013-12-13 Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study OHTA, SHOICHIRO YASUNO, NOBUHIRO INOMOTO, YUKI MATSUDA, KAORI NAKAGAWA, YOSHIHIKO SASAGAWA, ISOJI TANAKA, MASAHIKO Exp Ther Med Articles Several clinically approved recombinant erythropoietin (rEPO) preparations, such as epoetin-β, epoetin-δ and the epoetin-α derivative, darbepoetin-α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market. In 2010, epoetin-κ, which is biosimilar to epoetin-α, was clinically approved. Epoetin-κ is a biopharmaceutical product that is based on serum-free media following master cell bank preparation. The present study analyzes the results obtained during a six-month observation period, in which the administration of epoetin-β was switched to that of epoetin-κ. In a cohort of patients receiving chronic dialysis, who were clinically in a state of relative calm and were in control of their renal anemia, it was possible to sustain good control of the anemia by reducing the frequency of the epoetin-β administration from the conventional and empirically determined three times a week to twice a week, and further to once a week. Furthermore, the good control was maintained upon changing from the administration of epoetin-β to that of epoetin-κ. Moreover, three months subsequent to this switch, the degree of instability observed among the patients had decreased. Despite the fact that the situation following the changeover requires further investigation, it may be concluded that the results obtained in this study are indicative of the clinical equivalence and efficacy of epoetin-κ. D.A. Spandidos 2014-01 2013-11-06 /pmc/articles/PMC3861354/ /pubmed/24348759 http://dx.doi.org/10.3892/etm.2013.1384 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles OHTA, SHOICHIRO YASUNO, NOBUHIRO INOMOTO, YUKI MATSUDA, KAORI NAKAGAWA, YOSHIHIKO SASAGAWA, ISOJI TANAKA, MASAHIKO Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
title | Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
title_full | Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
title_fullStr | Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
title_full_unstemmed | Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
title_short | Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study |
title_sort | efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: a retrospective study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861354/ https://www.ncbi.nlm.nih.gov/pubmed/24348759 http://dx.doi.org/10.3892/etm.2013.1384 |
work_keys_str_mv | AT ohtashoichiro efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy AT yasunonobuhiro efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy AT inomotoyuki efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy AT matsudakaori efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy AT nakagawayoshihiko efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy AT sasagawaisoji efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy AT tanakamasahiko efficacyofonceortwiceweeklyadministrationofepoetinkinpatientsreceivinghemodialysisaretrospectivestudy |